Coyote Bioscience Co., Ltd. (“Coyote”) is a Chinese innovative high-tech company that has been engaged in molecular diagnostics for more than a decade. It excels in fast nucleic acid detection technology for microorganisms. With its patented core technologies, the company was able to participate in joint development of many interdisciplinary areas such as instruments, reagents, system platforms, artificial intelligence and big data. Coyote was founded in 2009, with its headquarters and R&D center in Beijing and an 8,000 square meter GMP production base in Yixing, Jiangsu province. As a national high-tech enterprise and excellent team, the company has been awarded many honors such as “China’s Top 50 Most Valuable Enterprises for Investment”, “China’s Most Promising Enterprise”, and “Advanced Collective” for combating the COVID-19 pandemic by the Ministry of Industry and Information Technology in 2020. The company has successfully secured investments from a number of well-known investment agencies including Hillhouse Capital, Northern Light Venture Capital, SAIF Partners and Legend Star. Members to its core management and technical teams are graduates from renowned universities in China and abroad such as Peking University, Beijing Institute of Technology, Harvard University, the University of California and the Pennsylvania State University. The company also collaborates with eminent academicians including Zhou Honghao, a leading expert in precision medicine, and Ouyang Qi from the School of Physics, Peking University, to provide technological support for project development. Coyote has awarded for 83 domestic and international patents, mainly including 22 international PCT patents, 13 domestically authorized patents, 2 US patents and 1 Australian patent. It has participated in the Torch Program of the Ministry of Science and Technology and national major programs for infectious diseases. The corporate vision, “Molecular Diagnostics for Everyone".
